FDA Clears Oropharyngeal Zapper Into Class II Medical Devices
Published Date: 6/1/2026
Rule
Summary
The FDA is officially putting the oropharyngeal electrical stimulator into Class II, meaning it has special safety rules but is easier to get to patients. This change helps make sure the device is safe and effective while cutting down on red tape, so more people can benefit from this cool tech. The new rules took effect on June 1, 2026, but the classification has been in place since September 2022.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Easier approval path for future devices
FDA's De Novo classification lets this device serve as a predicate so future oropharyngeal electrical stimulators can use the 510(k) process instead of a De Novo or premarket approval, which the FDA says reduces regulatory burden. The De Novo request was received April 19, 2022, and the device was classified on September 16, 2022.
Easier access to swallowing device
The FDA classified the oropharyngeal electrical stimulator as Class II with special controls, which the agency says will enhance patients' access to the device and reduce regulatory burdens. The final order is effective June 1, 2026, and the classification was applicable on September 16, 2022.
New testing, labeling, and 510(k) duties
To fall within Class II, oropharyngeal electrical stimulators must meet special controls such as non-clinical performance testing (electrical output, mechanical integrity, oxygen safety), biocompatibility, sterility and shelf-life testing, reprocessing validation, software verification and hazard analysis, electromagnetic compatibility, training programs, usability testing, and labeling that includes shelf life. FDA also states the device is subject to premarket notification under section 510(k).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10891 — Atlantic Highly Migratory Species; Atlantic Bluefin Tuna Fisheries; Harpoon Category Retention Limit Adjustment
Starting June 1, 2026, fishermen using harpoons to catch Atlantic bluefin tuna can only keep up to 5 big tuna per day instead of 10. This rule helps protect tuna populations and lasts until November 15, 2026, unless changed earlier. It affects all vessels with Harpoon category permits and aims to balance fishing fun with smart conservation.
Next: 2026-10895 — Standard Instrument Approach Procedures, and Takeoff Minimums and Obstacle Departure Procedures; Miscellaneous Amendments
Starting June 1, 2026, the FAA is updating how pilots approach and take off from certain airports to keep flights safe and smooth. These changes affect pilots and airports by adjusting flight paths and rules based on new tech and obstacles. No big costs here—just smarter, safer skies for everyone flying under instrument rules!